Rivers, E;
Worth, A;
Thrasher, AJ;
Burns, SO;
(2019)
How I manage patients with Wiskott Aldrich syndrome.
British Journal of Haematology
, 185
(4)
pp. 647-655.
10.1111/bjh.15831.
Preview |
Text (Article)
Thrasher How I manage WAS plain manuscript.pdf - Accepted Version Download (721kB) | Preview |
Preview |
Text (Figure)
Thrasher How I manage WAS plain figures.pdf - Accepted Version Download (687kB) | Preview |
Abstract
Wiskott Aldrich syndrome (WAS) is a primary immunodeficiency disease resulting in recurrent infections, eczema and microthrombocytopaenia. In its classical form, significant combined immune deficiency, autoimmune complications and risk of haematological malignancy necessitate early correction with stem cell transplantation or gene therapy. A milder form, X‐linked thrombocytopaenia (XLT), shares similar bleeding risk from thrombocytopaenia but is not associated with other significant clinical features and is generally managed conservatively. Here, we detail our approach to the diagnosis and treatment of classical WAS and XLT.
Archive Staff Only
 |
View Item |
